Research programme: anticancer therapeutics - Galaxy Biotech

Drug Profile

Research programme: anticancer therapeutics - Galaxy Biotech

Alternative Names: Anti-DR4 mAbs; Anti-DR5 mAbs; Anti-FGF2 mAbs; Anti-FGFR2 mAbs; Bispecific antibodies of DR-4 mAbs; Bispecific antibodies of DR-5 mAbs; GAL-F2; GAL-F2 mAb; GAL-F21 mAb; GAL-FR21; HuD-114; HuG-4.2; HuGAL-F2; HuGAL-FR21

Latest Information Update: 19 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galaxy Biotech
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Death domain receptor agonists; Fibroblast growth factor inhibitors; Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 20 Jun 2011 Research programme: anticancer monoclonal antibodies - Galaxy Biotech is available for licensing as of 20 Jun 2011.
  • 06 Apr 2011 Preclinical pharmacodynamics data in Cancer presented at the 102nd Annual Meeting of the American Association for Cancer Research (102nd-AACR-2011) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top